untitled

... 2... 2... 2... 3... 3... 5... 5... 5... 7... 8... 8... 8... 27... 30 HIS... 65... 72... 77... 77... 82... 114... 114... 116... 123... 124... 126... 126... 126 1

30 2011 2012 2 100 770 GDP 7,300 12 6,290 10.6 1 3 10 1 3 1 (2013)1 =17.3 2014 1 16 2

/ / / 2 Oncoplastic Breast Surgery 3 3

1 4

12 2 / 2 3 /2016 2013 2013 5

3 2013 4 2013 6

5 / 7 / /

1 23 4HIS5 4 7 6 2013 10 31 11 1 2013 11 19 11 21 5 4 2013 3 8

30 5 5 2000/5/15 / 11 9

7 () 10

6 7 8 25% 3 1 3 2 6 7 35 CEPA 100 7 2001/3/15 48 8 2001/7/22 311 11

7 12

5 9 2,000 30 20 2012 4 13 HP ( ) 10 8 9 2 10 http://www.chinalaw.gov.cn/article/cazjgg/201204/20120400363197.shtml 13

1 17.3 11 2,000 25% 2,500 4.3 2013 3 华 执 业 师 华 护 办 11 1=17.3 2014 1 16 14

1 4 1 3 4 12 13 )([1994]30 30 ) 30 ()30 30 30 30 30 30 12 疗 术 临 应 术 级 规 试 http://www.szhpfpc.gov.cn/open/web_edit_file/20120201100856.doc 13 [1994] 30 1994 9 2 2010 8 2 2011 3 15 12 5 15

1 3 2 1 2 3 1 3 3 1 3 3 9 3 500 1:3:5:7 14 2011 81 3 15 2 100 499 1:2:4:8 14 15 16

9 100 3 100 17

10 + 3 2 () 18

10 A. 35 4 40 + 44 45 B. 16 ++ C.200421 37 3 3 6 19

400 6 2 1 10 11 20

11 21

22

2 4 2 8 23

12 2 2 4 2 8 8 3 24

2011 1 () 13 25

100 2 13 16 26

2013 2013 10 14 27

17 设 计 规 GB50098-98 设 计 规 GBJl6-87 设 计 规 GB50222-95 节 设 计 标 GJ26-95 设 计 规 GBJll8-88 设 计 标 GBJl33-90 设 计 标 GB/T50033-2001 综 设 计 规 JGJ49-88 设 计 规 GB50057-94 设 计 规 JGJ50-2001 洁 净 术 术 规 GB50333-2002 设 标 结 构 载 规 GB50009-2001 设 计 规 GB50011-2001 结 构 设 计 规 GB50010-2002 钢 结 构 设 计 规 GB50017-2003 电 统 设 计 规 GB50052-2009 压 电 设 计 规 GB50054-2011 设 计 规 GB50016-2006 设 计 规 GB50057-2010 电 设 备 电 设 计 规 GB50055-2011 设 计 标 GB50034-2004 综 线 统 设 计 规 GB50311-2007 电 统 术 规 GB50343-2012 压 户 电 规 DGJ08-100-2003 17 GBGB 28

设 计 规 GB50016 2006 风 调 节 设 计 规 GB50019 2003 污 综 标 GB 162971996 节 设 计 标 GB 50189-2005 术 规 DGJ-08-88-2006 给 设 计 规 GB50015-20032009 设 计 规 GB50016-2006 动 喷 灭 统 设 计 规 灭 设 计 规 (GB50140-2005 给 设 计 规 GB50013-2006 设 计 规 GB50014-20062011 污 处 设 计 规 30 4.0.4 3 29

MRICTX PET-CT PET-CT PET-CT MRI CFDA MRICT 3 500 30

15 MRI / MRI ECHELON (1.5TT ) TRILLIUM OVAL O (3T) 1.5T0.3T0.4T 3TTRILLIU3 UM OVAL 2015 16 ECHELON (1.5TMRI) 18 T 31

Vantage Titan 3T (3T) Vantage Titan (1.5T) 2014 Vantage Titan 3T CFDA Vantage Titan CFDA 17 Vantage Titan 3T (3T MRI) MRI CFDA MRI CT SCENARIA (64ch 126slice) 16ch 64ch 16ch 16ch CT (SUPRIA) 2015 18 SCENARIA (64ch 126slice CT) 32

Aquilion ONE Vision, Aquilion ONE (320row 640slice CT) Aquilion PRIME (80row 160slice CT), Aquilion CXL (64row 128slice) Aquilion RXL (16row 32slice), Alexion (16row 32slice) Alexion Access(4row 4slice) CFDA 19 Aquilion ONE ViSION (320row 640slice CT) MRI CFDA X ERCP X CURVISTAEXAVISTA DR X Radnext50 DR X Sirius X X C X VersiFlex 32KW Radnext32 X DCS-600EXV 33

20 DCS-600EXV 21 Radnext 50 22 CURVISTA 34

X CRDR PACS X CFDA 23 Digital Mammography AMLET 24 SYNAPSE X MULTIPURPOSE REMOTE CONTROL R/F SYSTEM Ultimax-i DREX-UI80(FPD) RADIOGRAPHIC SYSTEM MRAD-D50S RADREX-i X MGU-1000D Peruru DIGITAL Infinix-i INFX-8000V CFDA 35

25 Infinix-i INFX-8000V 26 MGU-1000D Peruru DIGITAL MRI CFDA HIVISION Ascendus HIVISION Preirus HIVISION Avius Noblus 36

27 Ascendus, Preirus, Avius, Noblus Prosound F75 Prosound 7 Prosound 6 F37 PreirusAviusNoblus 37

28 F75, α7, α6, F37 CFDA 29 Sonosite Edge 38

Aplio Aplio500, Aplio400, Aplio300 CFDA 30 Aplio500, Aplio400, Aplio300 MRI CFDA 31 39

MRI CFDA MRI PET-CT PET-CT MRI Hitachi Medical Systems Beijing Corporation(HMBC)(HMBC) MRI L-He L-He MRI 19 MRI L-He L-He 2013 10 Responsible Helium Administration and Stewardship Act http://www.nikkei.com/article/dgxnasfk18038_y3a310c1000000/ 40

33 32 41 8 6

MRI CT (HMBC) CT MRI MRI (HMBC) Hitachi Medical Systems Suzhou Corporation HMSC 34 HMS X PACS X MRI 42

Hitachi Medical (Guangzhou) Co.,Ltd. (HMGC) Elastography 35 (100) MRI 20 43

PET-CT. PET-CT PET-CT 1 2002 GE 2009 6 PET-CTT PET-CT & PET 116 Cyclotron64 2010 PET-CT 127 PET 14 Cyclotron70 100 11.5 PET-CT PET-CT 2,000 2005 PET-CT 1317 PETT 2005 PET 49 13 ~20 2010 141 2012 170 Cyclotron FDG 36 PET-CT 140 120 100 80 60 40 20 0 3 0 2 2001 127 PET 105 PET-CT 88 Cycrlotron 74 70 53 53 56 477 40 34 30 23 15 18 12 4 4 7 6 7 9 10 11 121 13 14 2002 2003 2004 2005 2006 2007 20082 2009 2010 PET PET-CT PET-CT 6 PET 6 44

PET-CT 37 PET-CT Max. Min. Max. Min. 2006 ( 10 ) 2009 ( 114 ) 11,000 9,248 6,980 10,000 6,300 4,260 13,000 8,826 6,370 11,640 6,020 3,500. PET/PET-CT PET-CT 1,000 / 3 1,000 3,500 / 500 800 / 5,000 5 SPECT 3 2,000 CTMRI 21 21 45

PET- CT FDG FDG FDG 2006 CFDA CFDA Cyclotron FDG FDG 2 FDG 2 HTA AMS HTA AMS AMS 4 FDG FDG FDG FDG 2 AMS PET-CT FDG 46

38 FDG AMS LTD ( 电 ) 2 Mr. 01067855617-819 Mr. 13901252674 HTA401 2-3 Mr. 13911785412 PET 39 PET PET or PET-CT PET-CT GE GE PET-CT GE GE PET-CT GE GE PET-CT GE PET-CT Siemens CTI PET GE GE PET-CT Siemens PET-CT GE 潍 PET-CT Siemens CTI PET 47

FDG 20 FDG FDG 40 PET-CT FDG PET-CT 7500 / 10,00012,000 / 370MBq (10mCi) 10% 370MBq (10mCi) 10% 100 /mci 150 /mci 1015mCi 2030mCi 100 500600 1,0002,000 1015mCi 2030mCi 200 2,0003,000 48

1 3 3 8 5 3 1 2 1 3 2 3 HJ/T61-2001 ( 辐 环 监 测 术 规, 项 环 验 办 ) X X 2mm 1mm CT 49

16cm 2.35t/m 3 24cm 1.65t/m 3 2 20cm 2.35t/m 3 37cm 1.65t/m 3 2.5 1 1 X 3 1. 2. 3. X X CT A B PG LZ TESTC D E F G H I J HbA1c 22 22 16 50

2004 CFDA OC 41 OC PG 23 LZ TEST 99 I II 2 I/II I/II 2006 CFDA PG IVD CFDA LZ TEST PG III 23 pepsinogenpg 24 IVDin vitro diagnostics 51

42 LZ TEST PG III () LABOSPECT008 CFDA 43 LABOSPECT008 52

3 SAMPLE PRE-ANALYTICAL MODULAR SYSTEM SAMPLE PRE-ANALYTICAL MODULAR SYSTEM CFDA 44 SAMPLE PRE-ANALYTICAL MODULAR SYSTEM () CFDA 53

45 () () () 1 CFDA 46 () 54

XN-1000 CFDA 47 XN-1000 PTAPTT PT APTT CA-620 CFDA 55

U CFDA UT-10 A 56 48 CA 49 UT A-620 T-10

HbA1c HbA1c A1c HbA1c HLC-723 G8 CFDA 50 HLC-723 G8 57

51 HbA1c G 2006 CFDA 58

2,590 /800 /25,000 / Doctor 2,642 /1,500 /10,000 / 2,143 /1,500 /6,500 / 2,139 /1,500 /4,000 / 52 2% 1% 2% 6% 21% 29% 39% 1,0002,000 2,0003,000 3,0004,000 4,0005,000 5,0006,000 6,0007,000 59

IVD 53 IVD 25 25 60

54 2 61

() 55 62

56 63

4 100 60 3 1) 2) 3) 2012 12 ( ) 26 Bai du 临 检 验 师 试 http://baike.baidu.com/view/9521752.htm 64

HIS A. B. (HIS) PC PC 65

J JBCN 57 66 IBM JBC LENOVO CC O JB JBCN BCC JBCN

58 JBCC 59 JBCC JBCN JBCN 67

JBCN 24 365 24 365 24 365 1.5 2 3 A. 24 365 JBCN JBCN 68

DICOM3.0 69

I/F DICOM3.0 JBCN 110Mbps VPN 70

VPN 60 JBCC 71

2 2 2 2530 15 72

61 27 5,000 7,000 10,000 2,0003,000 1,0005,000 27 73

62 JETRO 8 40 2 36 150% 200 300 1 3 1 1 1 1 3 63 1 10 5 10 20 10 20 15 74

5 18 1 10 28 2008 14 2 2 3 2008 3 1 29 19 3 1 1 1 3 2 3 6 6 1 28 29 75

3 2 2 6 20 90 76

2003 2007 32 10 41.64 64 64 2003-2007 ALL2003-2007 41.64 49.17 16.16 2008 90.75 现 - 32 肿 记 2003-2007 资 报 肿 2012 32 6 http://ganjoho.jp/professional/statistics/statistics.html#02 10 65.58 10 59.43 10 57.60 65 77

65 2003-2007 32 57.60 4.60 48.74 38.20 59.43 兴 38.78 53.77 21.60 37.63 40.22 42.08 53.78 65.58 23.49 现 - 32 肿 记 2003-2007 资 报 肿 2012 32 6 662008 10 90.75 66 10 100 90 80 70 60 50 40 30 20 10 0 85.99 90.75 73.73 72.74 76.06 66.93 44.6 47.38 50.02 50.75 52.23 37.1 40.00 42.18 43.1 45.18 14.39 15.26 15.24 16.15 19.73 2003 2004 2005 2006 2007 2008 ALL 现 - 32 肿 记 2003-2007 资 报 肿 2012 32 6 http://ganjoho.jp/professional/statistics/statistics.html#02 78

67 1.5 10 49.17 10 41.64 A 10 90.75 B 67 A B 49.17/10 90.75/10 41.64/10 90.75/10 770 386 244 1,897 1,198 3,501 2,211 9,580 4,712 1,978 20,141 8,617 42,762 18,022 135,404 66,009 34,701 274,861 170,624 599,045 314,918 2013 (2012 ) 2013 2012 A 1,897 20,141 274,861 1,198 8,617 170,624 B 3,501 42,762 599,045 2,211 18,022 314,918 2008 1 25 1222 86180 1,7063,149 500 1% 维 读 费 时 锡 专 栏 2010 79

5% 10 31 1 2 Radiofrequency Ablation: RFAHigh Intensity Focused Ultrasound: HIFU 10 68 10 10 31 协 http://www.caca.org.cn/system/2010/10/19/010060689.shtml 32 刘 刘 谭 综 疗 现 肿 杂 2013 2 5 1 80

68 复 30-40% 48% 43 2012 4 33 http://www.tjmuch.com/ksjs/ 34 复 http://www.shca.org.cn/dazhong/room# 35 http://www.bddyyy.com.cn/ksyl/qtks/zlhl/20091202/2770.shtml 36 http://www.pumch.cn/ksyl/wkxx/rxwk 37 http://www.anti-cancer.com.cn/class8.asp?id=75&ksmc= 38 301 http://www.301hospital.com.cn/web/main/wjfw.html 39 http://www.sysucc.org.cn/dept_web.aspx?did=13 40 307 http://www.307hospital.com/index.asp 41 http://www.hrbmutumour.cn/breast.asp 42 http://www.rjh.com.cn/2013ruijin/ruijin/ylts/lcks/6501.shtml 43 http://www.kameda-health.com/cancer/patient/cancer/breast/result/index.html 81

69 3 VIP 23 16 70 10 8 401 3 44 http://bddsb.bandao.cn/data/20120608/html/63/content_1.html 45 http://www.qdzxyy.com/sub_keshi_show.aspx?id=27&ppid=97 46 http://qdslyy.qdslyy.cn/room_list.aspx 47 http://www.qdby.com/keshi/&frontcomcontent_list01-1282521998243contid=0cd25569-8c7f-4d46-96 32-d2ab78943c77&comContentId=0cd25569-8c7f-4d46-9632-d2ab78943c77&comp_stats=comp-FrontComC ontent_list01-1282521998243.html 82

16 15 web 70 1 东 5 2 401 闽 22 3 2 4 1 49 5 阳 4 6 12 7 苏 17 8 汇 77 9 2 10 12 2 201 11 预 东 175 12 伤 东 128 13 检 4 14 127 15 崂 3 16 沧 84 17.7 17.8 17.7 60 41 OL VIP 1 2 83

71 伤 12 60 401 11 17 12 17.8 20 8 预 2 2 16 28 41 17.7 汇 12 7 248 17.7 web 248 7 500 1,000 32% 500 31% 84% 2,000 35,000 48 55,650 5,000 3 401 2,000 3 汇 6 48 117.3 2014 1 16 84

72 N=248 web B C 2 2,000 4 16% 73 2,843 49,183 2,297 39,738 55,650 85

73 N=20 web B C 74 7 2,000 7 MRI MRI 86

74 ALL N=2482,000 N=40 web 87

88 75 N=248 79% 62% 87% 86% 73% 100% 100% 100% 90% 73% 97% 98% 100% 100% 100% 100% 39% 26% 27% 53% 64% 78% 100% 67% 91% 74% 100% 96% 100% 100% 100% 100% 4% 1% 0% 6% 9% 11% 33% 17% 94% 81% 100% 100% 100% 100% 100% 100% 50% 38% 51% 57% 68% 44% 67% 50% B 25% 5% 22% 35% 59% 67% 67% 17% C

89 49% 15% 51% 61% 100% 100% 67% 100% 27% 5% 18% 47% 50% 89% 67% 67% 90% 74% 99% 100% 91% 100% 67% 100% 21% 0% 10% 27% 68% 78% 67% 100% 68% 50% 75% 76% 64% 89% 100% 100% 46% 24% 51% 51% 50% 89% 100% 100% 18% 3% 11% 25% 36% 56% 67% 83% 83% 72% 87% 88% 100% 100% 67% 67%

90 10% 0% 5% 16% 27% 44% 67% 33% 29% 9% 29% 41% 55% 56% 67% 17% 1% 0% 0% 0% 5% 0% 0% 33% 94% 82% 100% 100% 100% 100% 67% 100% 42% 10% 37% 61% 91% 100% 67% 100% 38% 4% 35% 65% 73% 78% 67% 83% 0% 0% 0% 0% 0% 0% 0% 17% PET-CT

22% 100% 100% 100% 100% 71% 74% 65% 0% 0% 0% 0% 0% 0% 4% 1% MRI 100% 100% 100% 100% 90% 87% 52% 81% 0% 0% 0% 20% 29% 32% 17% 24% 0% 0% 67% 75% 69% 40% 38% 49% 500 16 23 39 78 500 1,000 30 31 18 79 1,000 2,000 16 21 14 51 2,000 3,000 8 10 4 22 3,000 4,000 3 3 3 9 4,000 5,000 1 2 3 5,000 1 1 4 6 75 91 82 248 N 91

9 49 3 web 81% 2,000 765,000 26% 10,000 3 VISTA 76 web 3,995 69,112 3,000 51,900 2,843 2,297 1,000 2,000 77 C 40 49 http://dalian.china-town.tv/modules/hospital/index.php?content_id=33 92

51 77 87% 100% 87% 100% 87% 100% 93% 87% 84% 98% 78% 93% 72% 85% 69% 98% 66% 88% 62% 64% 13% 63% 54% 100% 51% 100% 50% 93% 46% 78% 43% 70% B 43% 60% 35% 75% 32% 75% 22% 70% 21% 50% 16% 35% 6% 63% 6% 30% C 4% 55% 8% 4% 0% 0% N40 0% 0% N68 MRI 0% 0% 0% 20% 40% 60% 80% 100% web PET-CT PET-CT PET-CT 93

PET-CT 50 2010 127 PET-CT 94 7 PET-CT 1 2 3 4 78 PET-CT 3 9 6 GE PET-CT 79 PET-CT 8,844 153,000 8,849 8,000 9,000 7,000 11,767 5,000 7,000 8 7 11,000 13,000 78 PET-CT 陕 PET-CT 预 约 http://www.petct114.com/ 50 PET-CT 预 约 http://www.petct114.com/ 94

79 PET-CT 岛 级 东 级 潍 级 级 东 级 东 肿 级 东 齐 鲁 级 顶 级 级 PET-CT 预 约 http://www.petct114.com/ PET-CT 1 GE PET-CT PET-CT 1 2 3 PET-CT 3 51 3 PET-CT PET-CT 51 3 501 95

2014 1 27 1 30 N=515 20 1 5000 1 1.5 A B A X B CTMRIMRA CT 3D-CT CTPET-CT MRIHPV PSA 5 20 1 5,000 1 5,000 1 12% 5% 96

80 103 17 17% 103 14 14% 103 5 5% 30 7 23% 13 2 15% 18 1 6% 39 2 5% 409 48 12% 2014 1 14 1 17 20 1 5,000 770 1 5% 9 3.5 / 16 1 1 2200 260 1 1 8 2013 98% 81 86% 82 97

81 82 98

7 83 6 83 6 4 web 99

84 85 7 7 100

101 86 70% MRIHPV N=245PSA N270 86.2 95.7 88.7 41.4 74.2 63.1 26.8 14.0 19.6 34.2 21.2 13.2 15.7 24.5 79.0 59.4 33.0 87.4 85.4 45.2 39.0 73.4 18.8 14.4 11.3 7.6 76.1 45.6 36.1 62.9 33.0 22.5 61.7 6.8 61.6 17.6 9.0 54.3 37.1 22.0 30.4 37.1 B C HIV CT MRIMRA X CT D-CT CT X MRI HPV PSA

6 87 8850% 39% 11% 1,000 32%1,000 2,000 33% 2 4,000 87 88 39% 11% 50% 0% 100% [Q11] N=496 102

89 4,000 5,000 10% 3,000 4,000 9% 5,000 7,000 3% 1,000 32% 7,0001 3% 1 1% 2,000 3,000 9% 1,000 2,000 33% N=194 1 90 3% 91 90 [Q7] n=515 23 3 13% 5% 30 13% 1 2 29% 301 40% 103

91 35 5 TOP5> 1.64.1% 2.62.3% 3.61.9% 4.61.6% 5.59.8% TOP5 3 42.9% 9 87.8% 92 104

92 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 1 11.7 32.6 28.2 22.7 4.9 11.3 12.4 35.0 30.1 11. 3 11.7 27.6 32.4 21.9 6.4 43.3 44.55 8.92.5 0.8 ()N= =515 95.2% 93 93 32 5 105

94 TOP3 9 1 95 64.1% 95 106

96 3 TOP5 97 7 7 7 17.6% 44.1% 107

97 70%5050% MRIHPV N=245PSA N270 108

4 2% 98 99 36% 98 22% 2% 5% 71% N=514 109

99 29 6 19 23 14 5 48 95 82 78 109 127 185 N=514 3 2 5 110

100 38.1% 56.9% 101 111

3,000 4,000 7,000 1 700 1,000 500 PSM 2,000 3,000 1,500 2,000 102 PSM N=515 103 1 2 3 5 112

1.5 1 103 N=515) 113

3 2013 12 10 11 2 3 21 1 7 104 21 3 3 1 1917 1984 2010 5 2,000 1,500 20 4,000 1,360 70 1 1 4 / 8,000 / 1220 / 200-250 / 100 / 40 / 3 复 2010 2012 3 1 53 2,000 1 7.2 114

105 1984 ODA 3 68 1,500 VIP 24 40 200 5050 800 1,500 3,800 100 51 21 21 21 1 2 95% 3% 2% / 8 1 115

106 3 3 107 21 1,000 3,000 VIP10,000-18,000 1,000 VIP10,000-18,000 200-250 / 100 / 40 / 95% 116

3 108 21 80% 10 7 10 15 12 4 1 4 2 10 2 2 4 21 109 21 CT MRI GE GE DR 52 53 PACS 52 DR digital radiography X 53 X X 117

2011 Wi-Fi CONSIS PACSSYNAPSE 110 110 2012 Lenovo OS Windows7 Wi-Fi 15 1,000 1998 2008 IOC 5 3D 3D 111 118

111 21 2012 IC 112 IC EXCEL 112 119

112 21 IC 2011 3 100 12 Windows WEB LANWi-Fi Wi-Fi ID IC WEB 120

85%3 10%3 5 2 CT MR CTMR PET-CT XP 56 CTMRIPET MDL 57 21 113 21 54 CT CT 55 MRI CTMR 56 XP(X-rayted Photograph ) X X 57 MDLMagendurchleuchtung X 121

113 30% 19% 70% 81% 109 GE MRICT 122

123

2016 2020 5 10,000 35 /PET-CT 2,400 8 / 500 12 / 1 1.5 3 95 3 5 7,200 96 23,000 114 124

2014 125

PET-CT FDG 2014 2014 web 2016 126

115 2014 127